- 63% of Americans consider Trump’s crypto income inappropriate
According to a survey, most Americans view Donald Trump and his family’s income from crypto projects as a conflict of interest while digital asset regulation is being discussed. The issue has reignited debate over the links between politics, personal business, and the crypto industry. - China gains access to Nvidia chips through overseas data centers
Despite U.S. export restrictions, Chinese companies continue using powerful Nvidia chips through cloud services and data centers outside China. This shows how technology sanctions can be bypassed through third-country infrastructure. - Toyota starts selling tokenized bonds through Toyota Wallet
Toyota has launched its first sale of digital bonds through its own Toyota Wallet app. The product allows investors to buy tokenized debt securities and shows how major corporations are testing blockchain in traditional finance. - SEC proposes new regulatory framework for crypto assets and token sales
The U.S. Securities and Exchange Commission introduced an approach aimed at simplifying token issuance and fundraising for crypto projects. The new framework would provide clearer rules for token sales, custody, and digital asset trading. - Amazon reportedly scanned and destroyed rare books to train AI
An investigation found that Amazon used rare printed books for digitization and AI model training, after which some copies were destroyed. The story drew criticism from librarians, researchers, and cultural heritage advocates. - X plans to pay creator monetization in stablecoins
According to media reports, X is considering stablecoin payouts for creators. The move could reduce fees, speed up international transfers, and become another example of crypto integration into social platforms. - AI drug patenting reaches a legal deadlock
Lawyers and pharmaceutical companies are facing a key question: who should be considered the inventor if an AI system proposes the core formula of a drug? The issue could significantly affect biotech, patents, and investment in AI-driven drug discovery.